

Ref. No: 2057
Date: 16/09/25
Subject: Giant cell arteritis

REQUEST

Q1. Does your trust or health board treat giant cell arteritis (GCA)? If not, please provide the name of the hospital or trust that you refer GCA patients to.

Q2. In the past 3 months, how many patients with a primary diagnosis of GCA (ICD10 codes M31.5 or M31.6) were:

- Admitted as an inpatient
- Treated in A&E

Q3. How many patients were treated by the rheumatology department in the past 3 months with the following:

- Tocilizumab – for any disease
- Tocilizumab for rheumatoid arthritis (RA) only
- Tocilizumab for giant cell arteritis (GCA) only

Q4. How many patients were treated by the ophthalmology department (for any disease) in the past 3 months with Tocilizumab?

Q5. How many patients were treated in A&E in the past 3 months for giant cell arteritis (GCA) with Tocilizumab?

RESPONSE

Admitted as an inpatient

Month	STHK Inpatient admissions	S&O Inpatient admissions	MWL Inpatient admissions
June	0	<5	<5
July	0	<5	<5
August	0	<5	<5

Attended A&E

Month	STHK A&E Attendances	S&O A&E Attendances	MWL A&E Attendances
June	<5	<5	6
July	<5	<5	7
August	<5	<5	<5

Q3. How many patients were treated by the rheumatology department in the past 3 months with the following:

- Tocilizumab – for any disease **60**

- Tocilizumab for rheumatoid arthritis (RA) only **20**
- Tocilizumab for giant cell arteritis (GCA) only **0**

Q4. How many patients were treated by the ophthalmology department (for any disease) in the past 3 months with Tocilizumab? **0**

Q5. How many patients were treated in A&E in the past 3 months for giant cell arteritis (GCA) with Tocilizumab? **0**